$CNTX Cashflow Statement | Understand Stock

$CNTX

$0.23 -$0.01 (2.17%) Close

$CNTX Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statement of Cash Flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Cash flows from operating activities:
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Acquired in-process research and development
Fair value of warrants for services provided
Research And Development Expense, Acquired In Process
Share-based compensation expense
Depreciation and amortization expense
Non-cash interest expense
Change in fair value of convertible promissory notes
Reduction in the carrying amount of operating lease right-of-use asset
Gain on extinguishment of debt
Changes in operating assets and liabilities:
Prepaid expenses and other current assets
Other assets
Accounts payable
Accrued expenses and other current liabilities
Operating lease liability

Cash used in operating activities
Cash flows from investing activities:
Acquired in-process research and development
Purchase of property and equipment
Cash used in investing activities
Cash flows from financing activities:
Proceeds from the issuance of convertible bridge notes
Proceeds from the issuance of note payable
Proceeds from the sale of common stock and prefunded warrants in private placement, net of offering costs
Proceeds from the sale of Series A preferred stock, net
Series Seed Preferred Stock
Series A Preferred Stock
Total proceeds from the sale of Series A preferred stock, net
Proceeds from the sale of common stock related to IPO, net
Payment of offering costs from the sale of common stock from ATM facility
Proceeds from the sale of common stock from ATM facility, net
Cash (used in) provided by financing activities

Net (decrease) increase in cash and cash equivalents
Cash and cash equivalents at beginning of period
Cash and cash equivalents at end of period
Supplemental disclosure of non-cash activities:
Cashless exercise of prefunded warrants from private placement
Unpaid offering costs in Accounts payable
Right-of-use asset acquired under operating lease
Conversion of convertible promissory notes, including accrued interest, to Series A preferred stock
Demand Notes to Convertible Promissory Notes
Bridge Notes to Series A Preferred Stock
Convertible Promissory Notes To Series Seed Preferred Stock
Total conversion of convertible promissory notes, including accrued interest, to Series A preferred stock
Issuance of warrants in conjunction with Series A preferred stock
Series A preferred stock issued for acquired in-process research and development
Deferred offering costs in accounts payable and accrued expenses
Change in fair value of redeemable common stock to redemption value
Conversion of preferred stock and redeemable common stock upon IPO

Comments